Literature DB >> 10231377

The expression of both domains of the 69/71 kDa 2',5' oligoadenylate synthetase generates a catalytically active enzyme and mediates an anti-viral response.

I Marié1, D Rebouillat, A G Hovanessian.   

Abstract

The 2',5' oligoadenylate synthetase (OAS) represents a family of interferon-induced proteins which, when activated by double-stranded (ds) RNA, polymerizes ATP into 2',5'-linked oligomers with the general formula pppA(2'p5'A)n, where n >/= 1. The 69-kDa form of human OAS has two isoforms (p69 and p71) that are identical for their first 683 amino acids and consist of two homologous and adjacent domains, each homologous to the small 40-kDa OAS. Here, we demonstrate that mRNA species specific for the isoforms p69 and p71 are enhanced in interferon-treated cells, with the p69 mRNA being more abundant than that of p71. In transfected cells, both isoforms could be expressed independently to generate enzymes with similar catalytic activity, typical of the natural 69-kDa OAS from interferon-treated cells. On the other hand, deletion mutants expressing either the N- or C-terminal domain common in p69 and p71 were greatly unstable and were found to be devoid of catalytic activity, in spite of the capacity of the C-terminal domain to bind dsRNA. Finally, we show that murine cell lines stably expressing either p69 or p71 isoforms partially resist infection by the encephalomyocarditis virus. These results indicate that both isoforms of the 69-kDa form of 2',5' OAS are expressed in interferon-treated cells, and that each isoform could be implicated in the mechanism of the anti-viral action of interferon.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231377     DOI: 10.1046/j.1432-1327.1999.00361.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.

Authors:  Xiaowen Su; Leland J Yee; KyungAh Im; Shannon L Rhodes; YongMing Tang; Xiaomei Tong; Charles Howell; Darmendra Ramcharran; Hugo R Rosen; Milton W Taylor; T Jake Liang; Huiying Yang
Journal:  J Hepatol       Date:  2008-05-20       Impact factor: 25.083

Review 2.  RNA regulation of the antiviral protein 2'-5'-oligoadenylate synthetase.

Authors:  Samantha L Schwartz; Graeme L Conn
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-04-15       Impact factor: 9.957

Review 3.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Structural mechanism of sensing long dsRNA via a noncatalytic domain in human oligoadenylate synthetase 3.

Authors:  Jesse Donovan; Gena Whitney; Sneha Rath; Alexei Korennykh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

5.  IFN-β1b induces OAS3 to inhibit EV71 via IFN-β1b/JAK/STAT1 pathway.

Authors:  Baisong Zheng; Xiaolei Zhou; Li Tian; Jian Wang; Wenyan Zhang
Journal:  Virol Sin       Date:  2022-08-05       Impact factor: 6.947

6.  PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

Authors:  Yunqing Li; Fadila Guessous; Sherwin Kwon; Manish Kumar; Opeyemi Ibidapo; Lauren Fuller; Elizabeth Johnson; Bachchu Lal; Isa Hussaini; Yongde Bao; John Laterra; David Schiff; Roger Abounader
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

7.  Structural and Hydrodynamic Characterization of Dimeric Human Oligoadenylate Synthetase 2.

Authors:  Amit Koul; Darren Gemmill; Nikhat Lubna; Markus Meier; Natalie Krahn; Evan P Booy; Jörg Stetefeld; Trushar R Patel; Sean A McKenna
Journal:  Biophys J       Date:  2020-05-01       Impact factor: 4.033

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.